Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer

被引:31
作者
Wang, Jianjie [1 ,3 ]
Li, Qingwang [1 ,2 ]
Ou, Yetao [1 ,3 ]
Han, Zengsheng [1 ]
Li, Kun [1 ]
Wang, Peijun [1 ,3 ]
Zhou, Shaobo [4 ]
机构
[1] Yanshan Univ, Dept Biol Engn, Coll Environm & Chem Engn, Qinhuangdao 066004, Peoples R China
[2] NW A&F Univ, Sch Anim Sci, Yangling 712100, Peoples R China
[3] Jiamusi Univ, Coll Basic Med, Jiamusi 154007, Peoples R China
[4] Univ Bedfordshire, Inst Res Appl Nat Sci, LIRANS, Luton LU2 8DL, Beds, England
关键词
Lactoferrin; Adenovirus vector; Gene therapy; Breast cancer; Apoptosis; Pathway; BOVINE LACTOFERRIN; MECHANISMS; EXPRESSION; INDUCTION; CARCINOMA; IMMUNE; DEATH; BCL-2; MILK; FAS;
D O I
10.1007/s12272-011-0616-z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human lactoferrin (hLTF), an 80-kDa iron-binding glycoprotein, has antitumor activity. In this study, a recombinant adenovirus containing the human lactoferrin cDNA (ad-rhLTF) was constructed and its effect on tumor growth was investigated in mice bearing EMT6 breast cancer. Ad-rhLTF was injected seven times within 14 days into the tumor site at two concentrations (10(8) and 5 x 10(8) pfu/mL) in mice bearing EMT6 breast cancer. Injected ad-rhLTF had considerable cytotoxicity on mice breast cancer, and significantly reducing the weight of tumor produced and increasing the tumor inhibition rate up to 52.64%. The presence of apoptotic cells was confirmed using TUNEL staining and flow cytometry assays. At the same time, RTPCR and Western blot analyses demonstrated that ad-rhLTF also decreased expression of Bcl-2 and increased Bax and caspase 3 expressions. Therefore, we conclude that ad-rhLTF inhibits tumor growth by inducing tumor cell apoptosis in mice with breast cancer by triggering the mitochondrial-dependent pathway and activation of caspase 3. The results indicate that ad-rhLTF might be a promising drug for breast cancer gene therapy.
引用
收藏
页码:987 / 995
页数:9
相关论文
共 29 条
[1]   Orally administered lactoferrin restores humoral immune response in immunocompromised mice [J].
Artyrn, J ;
Zimecki, M ;
Paprocka, M ;
Kruzel, ML .
IMMUNOLOGY LETTERS, 2003, 89 (01) :9-15
[2]   28-Day repeated dose oral toxicity of recombinant human holo-lactoferrin in rats [J].
Cerven, D. ;
DeGeorge, G. ;
Bethell, D. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2008, 52 (02) :174-179
[3]   Apotosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix [J].
Cheung, TH ;
Chung, TKH ;
Lo, KWK ;
Yu, MY ;
Krajewski, S ;
Reed, JC ;
Wong, YF .
GYNECOLOGIC ONCOLOGY, 2002, 86 (01) :14-18
[4]   Antiinflammatory activities of lactoferrin [J].
Conneely, OM .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2001, 20 (05) :389S-395S
[5]   Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats [J].
Fujita, K ;
Matsuda, E ;
Sekine, K ;
Iigo, M ;
Tsuda, H .
CARCINOGENESIS, 2004, 25 (10) :1961-1966
[6]   Lactoferrin: structure, function and applications [J].
Gonzalez-Chavez, Susana A. ;
Arevalo-Gallegos, Sigifredo ;
Rascon-Cruz, Quintin .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (04)
[7]  
Han ZS, 2008, J MICROBIOL BIOTECHN, V18, P153
[8]   High-level expression of human lactoferrin in the milk of goats by using replication-defective adenoviral vectors [J].
Han, Zeng-Sheng ;
Li, Qing-Wang ;
Zhang, Zhi-Ying ;
Xiao, Bo ;
Gao, Da-Wei ;
Wu, Shu-Yun ;
Li, Jian ;
Zhao, Hong-Wei ;
Jiang, Zhong-Liang ;
Hu, Jian-Hong .
PROTEIN EXPRESSION AND PURIFICATION, 2007, 53 (01) :225-231
[9]   Antitumor activity of the procyanidins from Pinus koraiensis bark on mice bearing U14 cervical cancer [J].
Li, Kun ;
Li, Qingwang ;
Li, Jian ;
Zhang, Tao ;
Han, Zhengsheng ;
Gao, Dawei ;
Zheng, Fulu .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 (07) :1145-1151
[10]   Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines [J].
Mader, JS ;
Salsman, J ;
Conrad, DM ;
Hoskin, DW .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) :612-624